Justin B Leong

Address:

87 Ledyard St, San Francisco, CA 94124

VIN:

WBAVB73557FV75358

Make:

BMW

Model:

3-Series 4dr Sdn 335i RW

Year:

2007

US Patent:

20200179431, Jun 11, 2020

Filed:

Oct 21, 2019

Appl. No.:

16/659093

Inventors:

- BERKELEY CA, US
David Kanne - Corte Madera CA, US
Leonard Sung - San Mateo CA, US
Kelsey Gauthier - Alameda CA, US
Laura Hix Glickman - Oakland CA, US
Justin Leong - Union City CA, US
Sarah M. McWhirter - Albany CA, US

Assignee:

ADURO BIOTECH, INC. - BERKELEY CA

International Classification:

A61K 31/7084
C07H 19/213
A61K 39/39
A61P 35/00
A61P 3/10
A61P 29/00
A61P 11/06
A61P 37/06
C07H 21/02
C07H 21/00

Abstract:

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.

US Patent:

20190062365, Feb 28, 2019

Filed:

Oct 28, 2016

Appl. No.:

15/771286

Inventors:

- Berkeley CA, US
- Basel, CH
Leonard SUNG - San Mateo CA, US
Kelsey GAUTHIER - Alameda CA, US
Laura Hix GLICKMAN - Oakland CA, US
Justin LEONG - Union City CA, US
Sarah M. McWHIRTER - Albany CA, US
Jeffrey McKENNA - Carlisle MA, US
Stephen M. CANHAM - Cambridge MA, US
Chudi Obioma NDUBAKU - Oakland CA, US

Assignee:

ADURO BIOTECH, INC. - Berkeley CA
NOVARTIS AG - Basel

International Classification:

C07H 21/04
C07H 21/02
A61K 45/06
A61K 39/39
A61P 35/00
A61K 39/395

Abstract:

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′- or 3′-mono-fluoro substituted, or 2′3′-di-fluoro substituted mixed linkage 2′,5′-3′,5′ CDNs.

US Patent:

20180369268, Dec 27, 2018

Filed:

Dec 16, 2016

Appl. No.:

16/062601

Inventors:

- Berkeley, CA
David KANNE - Corte Madera CA, US
Leonard SUNG - San Mateo CA, US
Justin LEONG - Union City CA, US
Sarah M. McWHIRTER - Albany CA, US

Assignee:

ADURO BIOTECH, INC. - BERKELEY CA

International Classification:

A61K 31/7084
G01N 33/50
A61K 45/06
A61K 39/39
A61K 35/17
C07D 307/04
C07D 273/02

Abstract:

The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.

US Patent:

20180064745, Mar 8, 2018

Filed:

Mar 9, 2016

Appl. No.:

15/556982

Inventors:

- BERKELEY CA, US
David Kanne - Corte Madera CA, US
Leonard Sung - San Mateo CA, US
Kelsey Gauthier - Alameda CA, US
Laura Hix Glickman - Oakland CA, US
Justin Leong - Union City CA, US
Sarah M. McWhirter - Albany CA, US

Assignee:

ADURO BIOTECH, INC. - BERKELEY CA

International Classification:

A61K 31/7084
A61K 39/39
C07H 19/213

Abstract:

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.